References 

1. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014 Oct 20;5:520. doi: 10.3389/fimmu.2014.00520. PMID: 25368619; PMCID: PMC4202688.

2. Chu TH, Patz EF Jr, Ackerman ME. Coming together at the hinges: Therapeutic prospects of IgG3. MAbs. 2021 Jan-Dec;13(1):1882028. doi: 10.1080/19420862.2021.1882028. PMID: 33602056; PMCID: PMC7899677.

3. Stapleton, N., Andersen, J., Stemerding, A. et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2, 599 (2011). https://doi.org/10.1038/ncomms1608

4. Dechavanne C, Dechavanne S, Sadissou I, Lokossou AG, Alvarado F, Dambrun M, et al. (2017) Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. PLoS Med 14(10): e1002403 https://doi.org/10.1371/journal.pmed.1002403

5. Izadi, Arman, et al. “Subclass-Switched Anti-Spike IgG3 Oligoclonal Cocktails Strongly Enhance Fc-Mediated Opsonization.” Proceedings of the National Academy of Sciences, vol. 120, no. 15, 3 Apr. 2023, https://doi.org/10.1073/pnas.2217590120. Accessed 19 Apr. 2023.

6. Lim, Yee Ying, et al. “Human IgG1 Fc PH-Dependent Optimization from a Constant PH Molecular Dynamics Simulation Analysis.” RSC Advances, vol. 10, no. 22, 2020, pp. 13066–13075, https://doi.org/10.1039/c9ra10712f. Accessed 20 July 2020.

7. Saito, Seiji, et al. “A Stable Engineered Human IgG3 Antibody with Decreased Aggregation during Antibody Expression and Low PH Stress.” Protein Science, vol. 28, no. 5, 22 Mar. 2019, pp. 900–909, https://doi.org/10.1002/pro.3598. Accessed 21 Dec. 2019.

8. Monnet, CeLine, et al. “Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.” Frontiers in Immunology, vol. 6, 4 Feb. 2015, https://doi.org/10.3389/fimmu.2015.00039. Accessed 19 Feb. 2024.

9. Shields, Robert L., et al. “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR.” Journal of Biological Chemistry, vol. 276, no. 9, 28 Nov. 2000, pp. 6591–6604, https://doi.org/10.1074/jbc.m009483200. Accessed 28 Dec. 2019.

10. Oganesyan, Vaheh, et al. “Structural Insights into Neonatal Fc Receptor-Based Recycling Mechanisms.” Journal of Biological Chemistry, vol. 289, no. 11, Mar. 2014, pp. 7812–7824, https://doi.org/10.1074/jbc.m113.537563. Accessed 15 Feb. 2022.

11. R.V. Honorato, P.I. Koukos, B. Jimenez-Garcia, A. Tsaregorodtsev, M. Verlato, A. Giachetti, A. Rosato and A.M.J.J. Bonvin (2021). "Structural biology in the clouds: The WeNMR-EOSC Ecosystem." Frontiers Mol. Biosci., 8, fmolb.2021.729513.

12. G.C.P van Zundert, J.P.G.L.M. Rodrigues, M. Trellet, C. Schmitz, P.L. Kastritis, E. Karaca, A.S.J. Melquiond, M. van Dijk, S.J. de Vries and A.M.J.J. Bonvin (2016). "The HADDOCK2.2 webserver: User-friendly integrative modeling of biomolecular complexes." J. Mol. Biol., 428, 720-725 (2015)

13. Vangone A. and Bonvin A.M.J.J. "Contact-based prediction of binding affinity in protein-protein complexes", eLife, 4, e07454 (2015).

14. Xue L., Rodrigues J., Kastritis P., Bonvin A.M.J.J.*, Vangone A.*, "PRODIGY: a web-server for predicting the binding affinity in protein-protein complexes", Bioinformatics, doi:10.1093/bioinformatics/btw514 (2016).

15. Dall’Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 281:23514–23524. doi: 10.1074/jbc.M604292200. 

PDB Structures Used

Wild Type IgG1: 5JII_1|Chains A, B|Ig gamma-1 chain C region|Homo sapiens (9606) 

IgG1 YTE (Engineered): 4N0U_4|Chain D[auth E]|Ig gamma-1 chain C region|Homo sapiens (9606)

Wild Type IgG3: 6D58_1|Chains A, B|Immunoglobulin heavy constant gamma 3|Homo sapiens (9606)

FcRn: 4N0U_1|Chain A|IgG receptor FcRn large subunit p51|Homo sapiens (9606)

Beta 2 Microglobulin: 4N0U_2|Chain B|Beta-2-microglobulin|Homo sapiens (9606)

Serum Albuminn: 4N0U_3|Chain C[auth D]|Serum albumin|Homo sapiens (9606)